EQS-News: APONTIS PHARMA successfully completes performance and efficiency improvement program


EQS-News: APONTIS PHARMA AG / Key word(s): Strategic Company Decision/Restructure of Company
APONTIS PHARMA successfully completes performance and efficiency improvement program

06.02.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA successfully completes performance and efficiency improvement program

  • New go-to-market approach comes into action earlier than planned on 1 March 2024
  • Headcount reduced from 185 to 110 employees
  • Expenses at EUR 5.6 million at lower end of planning – no further burdens in financial year 2024
  • Savings – based on a full 12-month period – amount to around EUR 6.5 million compared to 2023

Monheim am Rhein, 6 February 2024 – APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5) has successfully completed the performance and efficiency improvement program announced in summer 2023. The planned measures were implemented faster than expected. At the same time, expenses incurred were lower than planned. For the current financial year 2024, no further burdens are expected. The Company therefore views itself as being back on track to grow profitably once again and expand its leading position in the growing market for Single Pill combinations.

Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “At the end of the past year, we presented a comprehensive program to improve performance and efficiency, based on a thorough analysis of the weaknesses identified in the situation at the time. We are very pleased that we can announce the successful implementation of the agreed measures already at the beginning of the current year. By realigning our go-to-market approach to increase our operational strength while at the same time reducing the number of positions no longer required, we have set the course for growth and profitability in the future.”

New go-to-market approach for Single Pill combinations

Following APONTIS PHARMA's strong focus on establishing the Single Pill concept and the successful inclusion of Single Pill therapies in national and international treatment guidelines in Europe, the focus of future activities will be on individual Single Pill combinations and their specific applications. Physicians and stakeholders in the healthcare sector will be addressed, taking into account their specific requirements for innovative therapies. The scalable new go-to-market model includes the realignment of sales forces and a strengthening of medical and market access. The focus on physicians with high prescription potential enables full coverage of the relevant general practitioner target group with 50 sales representatives and a specialist sales force of 10 sales experts. Personal customer contact is supported and supplemented by comprehensive dialog marketing. The new go-to-market model will start on 1 March 2024, one month earlier than planned.

Expenses for performance and efficiency improvement program lower than planned – implementation completed ahead of expectations

The implementation of the performance and efficiency improvement program at EUR 5.6 million is at the lower end of the expenses planned for the 2023 financial year. By reaching an agreement with almost all employees at present, the necessary reduction in headcount from 185 to 110 employees could be negotiated. The corresponding savings will become noticeable in the course of the 2024 financial year; no further burdens are expected. Overall, the Company expects savings of around EUR 6.5 million over a full 12-month period, which is exactly in line with the original projection.

Bruno Wohlschlegel continued: “Following the implementation of the comprehensive performance and efficiency improvement program, APONTIS PHARMA is a new company. Without the commitment and willingness of our employees to support the necessary changes, these changes would not have been possible. The entire team is highly motivated to work in the new organizational structure. We expect the new go-to-market strategy for our Single Pill combinations to yield visible successes in the near future. Our upcoming product innovations will also benefit from this – we are expected to launch our 15th Single Pill combination on the German market in March 2024.”


CEO Bruno Wohlschlegel, CPO Thomas Milz, and CFO Thomas Zimmermann will explain the progress made in implementing the performance and efficiency improvement program in a webcast presentation today, 6 February 2024, at 10:00 CET. The presentation will be held in English.

Please register in advance to participate at:

APONTIS PHARMA Update Call Performance and Efficiency Program.

Figures for financial year 2023:

APONTIS PHARMA will publish the figures for the 2023 financial year on 28 March 2024.

Additional information:

Information on upcoming events can be found at https://apontis-pharma.de/en/financial-calendar and the latest analyst assessments at https://apontis-pharma.de/en/share-price.


APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients, while reducing complications, mortality and treatment costs. Consequently, Single Pills are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pills and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.


Investor Relations
[email protected]
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein


CROSS ALLIANCE communication GmbH
Sven Pauly
[email protected]
T: +49 89 125 09 0330

06.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Alfred-Nobel-Str. 10
40789 Monheim
E-mail: [email protected]
Internet: https://apontis-pharma.de/
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1830563

End of News EQS News Service

1830563  06.02.2024 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 54,71 44,80 40,04 39,24 51,18 55,73 36,96
EBITDA1,2 12,40 2,81 -1,72 1,00 2,36 5,57 -13,28
EBITDA-Marge3 22,66 6,27 -4,30 2,55 4,61 9,99
EBIT1,4 11,74 2,50 -2,29 -0,66 0,62 3,77 -15,16
EBIT-Marge5 21,46 5,58 -5,72 -1,68 1,21 6,77 -41,02
Jahresüberschuss1 11,58 2,37 -2,39 -1,18 -0,75 2,69 -12,68
Netto-Marge6 21,17 5,29 -5,97 -3,01 -1,47 4,83 -34,31
Cashflow1,7 31,09 4,46 -0,24 1,45 3,43 11,02 -12,60
Ergebnis je Aktie8 1,36 0,28 -0,28 -0,14 -0,09 0,32 -1,49
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: RSM Ebner Stolz

Apontis Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3CMGM 9,080 Kaufen 77,18
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
24,54 25,63 0,96 48,04
2,55 - 2,09 -4,46
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
0,00 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 09.08.2024 07.11.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
21,59% 65,81% 91,16% 7,58%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu APONTIS PHARMA AG  ISIN: DE000A3CMGM5 können Sie bei EQS abrufen

Gesundheit , A3CMGM , APPH , XETR:APPH